ES2587719T3 - Tratamiento contra la glomerulonefritis - Google Patents

Tratamiento contra la glomerulonefritis Download PDF

Info

Publication number
ES2587719T3
ES2587719T3 ES14158421.9T ES14158421T ES2587719T3 ES 2587719 T3 ES2587719 T3 ES 2587719T3 ES 14158421 T ES14158421 T ES 14158421T ES 2587719 T3 ES2587719 T3 ES 2587719T3
Authority
ES
Spain
Prior art keywords
compound
group
double bonds
formula
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14158421.9T
Other languages
English (en)
Spanish (es)
Inventor
Berit Johansen
Andrea Huwiler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coegin Pharma AS
Original Assignee
Avexxin AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avexxin AS filed Critical Avexxin AS
Application granted granted Critical
Publication of ES2587719T3 publication Critical patent/ES2587719T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/227—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES14158421.9T 2009-06-04 2010-06-04 Tratamiento contra la glomerulonefritis Active ES2587719T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0909643A GB0909643D0 (en) 2009-06-04 2009-06-04 Glomerulonephritis treatment
GB0909643 2009-06-04

Publications (1)

Publication Number Publication Date
ES2587719T3 true ES2587719T3 (es) 2016-10-26

Family

ID=40936918

Family Applications (2)

Application Number Title Priority Date Filing Date
ES14158421.9T Active ES2587719T3 (es) 2009-06-04 2010-06-04 Tratamiento contra la glomerulonefritis
ES10722643.3T Active ES2546198T3 (es) 2009-06-04 2010-06-04 Tratamiento contra la glomerulonefritis

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES10722643.3T Active ES2546198T3 (es) 2009-06-04 2010-06-04 Tratamiento contra la glomerulonefritis

Country Status (14)

Country Link
US (3) US20120136066A1 (enExample)
EP (2) EP2745837B1 (enExample)
JP (1) JP5837481B2 (enExample)
AU (1) AU2010256013B2 (enExample)
CA (1) CA2764465C (enExample)
CY (1) CY1118269T1 (enExample)
DK (2) DK2437739T3 (enExample)
ES (2) ES2587719T3 (enExample)
GB (1) GB0909643D0 (enExample)
HU (2) HUE030085T2 (enExample)
LT (1) LT2745837T (enExample)
PL (2) PL2745837T3 (enExample)
PT (2) PT2745837T (enExample)
WO (1) WO2010139482A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201014633D0 (en) * 2010-09-02 2010-10-13 Avexxin As Rheumatoid arthritis treatment
GB201205394D0 (en) 2012-03-27 2012-05-09 Adlens Ltd Improvements in or relating to deformable non-round membrane assemblies
GB201221329D0 (en) 2012-11-27 2013-01-09 Avexxin As Dermatitis treatment
GB201313238D0 (en) 2013-07-24 2013-09-04 Avexxin As Process for the preparation of a polyunsaturated ketone compound
GB201409363D0 (en) 2014-05-27 2014-07-09 Avexxin As Skin cancer treatment
GB201501144D0 (en) 2015-01-23 2015-03-11 Avexxin As Process for the preparation of a polyunsaturated ketone compound
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
CA3037582A1 (en) 2016-09-21 2018-03-29 Avexxin As Pharmaceutical composition
JP7305562B2 (ja) * 2017-06-16 2023-07-10 アヴェクシン エーエス 線維性疾患の治療のための組成物および方法
GB201910644D0 (en) 2019-07-25 2019-09-11 Coegin Pharma As Cancer Treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670465A (en) * 1986-05-21 1987-06-02 Syntex (U.S.A.) Inc. Arachidonic acid analogs
JPH0987176A (ja) * 1995-09-26 1997-03-31 Shiseido Co Ltd 糸球体腎炎抑制剤
JPH09268153A (ja) 1996-04-02 1997-10-14 Sagami Chem Res Center トリフルオロメチルケトン誘導体及びホスホリパーゼａ２阻害剤
WO1997038688A1 (en) * 1996-04-12 1997-10-23 Peptide Technology Pty. Limited Methods of treating immunopathologies using polyunsaturated fattyacids
US6107334A (en) 1998-02-23 2000-08-22 Wake Forest University Dietary control of arachidonic acid metabolism
WO2000002561A1 (en) 1998-07-13 2000-01-20 University Of South Florida Modulation of the phospholipase a2 pathway as a therapeutic
US6031014A (en) 1998-12-08 2000-02-29 Crivello; James V. Initiator compositions and methods for their synthesis and use
WO2002060535A1 (en) * 2001-01-31 2002-08-08 Leff Alan R Method of treating inflammatory conditions by inhibiting cytosolic phospholipase a¿2?
GB0202002D0 (en) * 2002-01-29 2002-03-13 Leiv Eiriksson Nyotek A S Use
MY131170A (en) * 2002-03-28 2007-07-31 Nissan Chemical Ind Ltd Therapeutic agent for glomerular disease
PL377614A1 (pl) * 2003-03-18 2006-02-06 Novartis Ag Kompozycje zawierające kwasy tłuszczowe i aminokwasy
NZ552238A (en) * 2006-12-20 2009-07-31 Seperex Nutritionals Ltd An extract
JP2010513469A (ja) 2006-12-20 2010-04-30 メドウェル ラボラトリーズ リミテッド ポリ不飽和脂肪酸とアミンの新規なコンジュゲート、およびその治療的使用
EP2217224B1 (en) * 2007-11-09 2019-05-08 Basf As Lipid compounds for use in cosmetic products, as food supplement or as a medicament

Also Published As

Publication number Publication date
HUE027050T2 (en) 2016-08-29
US8796251B2 (en) 2014-08-05
PT2745837T (pt) 2016-08-22
LT2745837T (lt) 2016-10-25
EP2437739A1 (en) 2012-04-11
CA2764465A1 (en) 2010-12-09
ES2546198T3 (es) 2015-09-21
US20120136066A1 (en) 2012-05-31
JP2012528813A (ja) 2012-11-15
PL2437739T3 (pl) 2015-11-30
PL2745837T3 (pl) 2017-01-31
AU2010256013A1 (en) 2012-01-12
HUE030085T2 (en) 2017-04-28
US9187396B2 (en) 2015-11-17
DK2437739T3 (en) 2015-08-17
EP2745837B1 (en) 2016-07-27
DK2745837T3 (en) 2016-08-29
US20100311843A1 (en) 2010-12-09
EP2437739B1 (en) 2015-07-29
US20140256824A1 (en) 2014-09-11
WO2010139482A1 (en) 2010-12-09
JP5837481B2 (ja) 2015-12-24
AU2010256013B2 (en) 2013-05-16
GB0909643D0 (en) 2009-07-22
PT2437739E (pt) 2015-10-12
CA2764465C (en) 2018-03-20
EP2745837A1 (en) 2014-06-25
CY1118269T1 (el) 2017-06-28

Similar Documents

Publication Publication Date Title
ES2587719T3 (es) Tratamiento contra la glomerulonefritis
CA2659956C (en) Inhibitors of pyruvate kinase and methods of treating disease
JP6258266B2 (ja) 障害を処置するための方法および組成物
CA2810102A1 (en) Rheumatoid arthritis treatment using polyunsaturated long chain ketones
JP2010530901A5 (enExample)
BRPI0922805B1 (pt) uso de um composto químiopreventivo para a fabricação de um medicamento para tratar psoríase
TW200916098A (en) Agent for lowering uric acid level
JP6562361B2 (ja) ベンゾチアゾール化合物及びこれを含有する医薬
ITMI962385A1 (it) Diaril-ciclometilenpirazoli farmacologicamente attivi procedimento per prepararli e composizioni farmaceutiche che li contengono
ES2811325T3 (es) Sal de sodio del inhibidor del transportador de ácido úrico y de su forma cristalina
JP6173352B2 (ja) 筋萎縮性側索硬化症の治療方法
JP2023505598A (ja) 化合物及びα１－アンチトリプシン欠損症の治療のためのそれらの使用
Romeiro et al. Synthesis, pharmacological evaluation and docking studies of new sulindac analogues
CN111417632B (zh) 噻唑-5-甲酸衍生物及其制备方法与应用
WO2019111897A1 (ja) 皮膚炎治療剤
JP7430879B2 (ja) アルブミン結合性を有するｎｏラジカル放出型抗がん剤としてのニトロ化フェニルカルボン酸誘導体
CN106946851B (zh) 一种用于预防和治疗肾结石的药物
WO2017170860A1 (ja) ヒートショックプロテイン４７阻害剤
Wang et al. Discovery and Optimization of Ester-linked Ibuprofen-Glycine Hybrids as the NF-κB Pathway Inhibitors for the Treatment of ulcerative colitis
WO2019159868A1 (ja) 大腸炎改善剤